Neurogene (NGNE) just unveiled an update.
Neurogene Inc. has announced that its groundbreaking NGN-401 gene therapy for Rett syndrome will be part of the FDA’s START Pilot Program, aimed at advancing rare disease therapeutics. This inclusion means the company will benefit from increased interaction with the FDA, gaining valuable guidance on clinical trial design and patient selection to optimize the development of their innovative treatment.
Learn more about NGNE stock on TipRanks’ Stock Analysis page.
